@article{Rudan_I-2022_96816,
title = {BNT162b2 COVID-19 vaccination uptake, safety, effectiveness and waning in children and young people aged 12–17 years in Scotland},
author = {Rudan, I. and Millington, T. and Antal, K. and Grange, Z. and Fenton, L. and Sullivan, C. and Buelo, A. and Wood, R. and Woolford, L. and Swann, O. and Murray, J. and Cullen, L. and Moore, E. and Haider, F. and Almaghrabi, F. and McMenamin, J. and Agrawal, U. and Shah, S. and Kerr, S. and Simpson, C. and Katikireddi, S. and Ritchie, S. and Robertson, C. and Sheikh, S.},
month = {sep},
year = {2022},
abstract = {BackgroundThe two-dose BNT162b2 (Pfizer-BioNTech) vaccine has demonstrated high efficacy against COVID-19 disease in clinical trials of children and young people (CYP). Consequently, we investigated the uptake, safety, effectiveness and waning of the protective effect of the BNT162b2 against symptomatic COVID-19 in CYP aged 12–17 years in Scotland.},
volume = {23},
journal = {The Lancet Regional Health - Europe},
publisher = {Elsevier},
url = {https://doi.org/10.1016/j.lanepe.2022.100513},
}
